Interleukin-21 mutant and its application

By introducing mutations into the amino acid sequence of interleukin-21 to form disulfide bonds and fusing them with anti-PD-1 antibodies, the selection and stability of existing IL-21 therapies are solved, and the affinity for IL-21 receptors is achieved. Reduces and improves the stability of fusion proteins, suitable for solid tumor treatment.

CN118598975BActive Publication Date: 2024-11-05CHENGDU CHIPSCREEN NEWWAY BIOSCIENCES CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411025537.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-05
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The existing interleukin-21 (IL-21) therapy is widely expressed on multiple cell surfaces, resulting in the lack of selectivity of exogenous recombinant IL-21, which has a short half-life and a greater therapeutic toxicity, and when fused with antibodies. Poor expression and stability.

Method used

An interleukin-21 mutant was designed to form disulfide bonds by introducing mutations at specific sites in the amino acid sequence and fusing with anti-PD-1 antibodies to form immunoconjugates to reduce the affinity for IL-21 receptors and improve expression and stability.

Benefits of technology

It significantly reduced the affinity of the interleukin-21 mutant for IL-21 receptor, increased the expression amount and stability of the fusion protein, decreased the tendency to aggregation, and improved the effectiveness of solid tumor treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118598975B_ABST
    Figure CN118598975B_ABST
Patent Text Reader

Abstract

The present application provides an interleukin-21 mutant and its application, belonging to the field of medical technology, wherein the mutant is a mutation of the 85th and 86th R (arginine) of the amino acid sequence of wild-type IL-21 to G (glycine), the 88th K (lysine) to G (glycine), the 90th R (arginine) to E (glutamic acid), the 5th R (arginine) and the 78th P (proline) are both mutated to C (cysteine), and a disulfide bond is formed between the two mutated C (cysteine). The mutant has a significantly reduced affinity for IL-21 receptors, and increases the expression of fusion heavy chains, improves stability, and reduces aggregation tendency. At the same time, the present application also provides related nucleic acid molecules, immunoconjugates, kits, pharmaceutical compositions, and the use of the interleukin-21 mutant or its immunoconjugate in the preparation of a drug for treating a subject with a solid tumor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular, relates to an interleukin-21 mutant and an application thereof. Background Art

[0002] Interleukin-21 (IL-21) is composed of four α-helical structures, belongs to the γc family, and consists of 134 amino acids. It is a pleiotropic cytokine that regulates the activity of innate and adaptive immune cells. IL-21 is mainly secreted by activated CD4+ T cells, NK cells, TFH cells, and Th17 cells. When IL-21 binds to the IL-21 receptor (IL-21R) / γc receptor complex, it can activate the JAK / STAT signaling pathway and regulate the differentiation, proliferation, activation of various immune cells such as NK, DC, B, T cells, and the production of different cytokines. However, the development of IL-21-based therapies is complex, including two directions of agonistic or antagonistic effects, targeting tumors and autoimmune diseases respectively, and including multiple product types such as antibodies, peptides, cell therapy, and oncolytic viruses.

[0003] For CD8+ T cells and NK cells, IL-21 can enhance their survival and cell-killing toxicity, and has great potential for synergistic anti-tumor effects. However, since the IL-21R / γc receptor complex is widely expressed on the surface of a variety of lymphocytes and hematopoietic cells, the administration of exogenous recombinant IL-21 is not selective, and IL-2 has a high affinity for IL21R, which will preferentially bind to and activate a large number of non-target cells in the periphery, resulting in a sink effect, resulting in a short half-life and greater therapeutic toxicity.

[0004] In addition, the four α-helices of IL-21 are connected by loops of different lengths, among which the CD loop is longer, more flexible, and rich in positively charged basic amino acids, resulting in poor drugability of recombinant IL-21. Therefore, IL-21 needs to be modified and fused to antibody expression to enhance specificity, reduce non-target affinity, and improve drugability.

[0005] Interleukin 21 has a high homology with IL-2, IL-4 and IL-15. The fusion of wild-type IL-21 or other modified IL-21 to the C-terminus of the heavy chain of the pembrolizumab antibody will lead to a decrease in the expression of the fused heavy chain, a low expression level of the antibody-fused IL-21, and poor stability. To solve the above problems, the application provides a new interleukin 21 (IL21) mutant fusion protein, which provides a variety of options for clinical application. Summary of the invention

[0006] The present invention provides an interleukin-21 mutant (IL-21) or an immunoconjugate thereof, and use thereof in the preparation of a medicament for treating a subject having a solid tumor.

[0007] On the one hand, the present application provides an interleukin-21 (IL-21) mutant, characterized in that, compared with wild-type IL-21, it comprises the following mutations: R (arginine) and K (lysine) in positions 85 to 90 RRQKHR of the amino acid sequence of wild-type IL-21 are mutated to G (glycine) or E (glutamate), R (arginine) at position 5 and P (proline) at position 78 are both mutated to C (cysteine), and a disulfide bond is formed between the two mutated C (cysteine); the amino acid sequence of the wild-type IL-21 is shown in SEQ ID NO.6.

[0008] In certain embodiments, the IL-21 mutant is as follows: the R (arginine) at positions 85 and 86 of the amino acid sequence of wild-type IL-21 is mutated to G (glycine), the K (lysine) at position 88 is mutated to G (glycine), the R (arginine) at position 90 is mutated to E (glutamic acid), the R (arginine) at position 5 and the P (proline) at position 78 are both mutated to C (cysteine), and a disulfide bond is formed between the two mutated C (cysteines).

[0009] In certain embodiments, the amino acid sequence of the IL-21 mutant is shown in SEQ ID NO:4.

[0010] In certain embodiments, the affinity of the IL-21 mutant for the IL-21 receptor (IL-21R) is significantly reduced compared to the affinity of wild-type IL-21 for the IL-21 receptor (IL-21R).

[0011] On the other hand, the present application provides an immunoconjugate, which comprises the aforementioned interleukin-21 mutant and an anti-PD-1 antibody.

[0012] In certain embodiments, the IL-21 mutant is attached to the Fc of the anti-PD-1 antibody directly or via a linker.

[0013] In certain embodiments, the IL-21 mutant is directly attached to the Fc of the anti-PD-1 antibody.

[0014] In certain embodiments, the IL-21 mutant is attached to the Fc of the anti-PD-1 antibody by a linker.

[0015] In certain embodiments, the IL-21 mutant is attached to the Fc of the anti-PD-1 antibody by a GGGGS (G4S) linker.

[0016] In certain embodiments, the IL-21 mutant is linked to the C-terminus of one of the two heavy chains of the anti-PD-1 antibody.

[0017] In certain embodiments, the anti-PD-1 antibody may be selected from Pembrolizumab, Nivolumab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab.

[0018] In certain embodiments, the anti-PD-1 antibody is pembrolizumab.

[0019] In certain embodiments, the anti-PD-1 antibody is Pembrolizumab modified by Knob-into-hole technology.

[0020] In certain embodiments, the Pembrolizumab modified by Knob-into-Hole technology (technology to prevent heavy chain mispairing) is that the 366th T (threonine) of the amino acid sequence of one of the heavy chains CH3 of Pembrolizumab is mutated to W (tryptophan); the 366th T (threonine) of the amino acid sequence of the other heavy chain CH3 is mutated to S (serine), the 368th L (leucine) is mutated to A (alanine), the 407th Y (tyrosine) is mutated to V (valine), and the 349th Y (tyrosine) is mutated to C (cysteine).

[0021] In certain embodiments, the immunoconjugate is a fusion protein comprising an IL-21 mutant and an anti-PD-1 antibody.

[0022] In certain embodiments, the fusion protein comprises: two light chains, each of which has an amino acid sequence as shown in SEQ ID NO:3; a heavy chain, the amino acid sequence of the heavy chain is shown in SEQ ID NO:1; and a heavy chain fused to an IL-21 mutant, the amino acid sequence of the fused heavy chain is shown in SEQ ID NO:5.

[0023] In certain embodiments, the fusion protein increases expression of the fusion heavy chain.

[0024] In certain embodiments, the fusion protein has improved stability.

[0025] In certain embodiments, the fusion protein has reduced propensity to aggregate.

[0026] On the other hand, the present application provides a kit comprising the mutant and / or immunoconjugate.

[0027] In certain embodiments, the present application provides a kit comprising the mutant.

[0028] In certain embodiments, the present application provides a kit comprising the immunoconjugate.

[0029] On the other hand, the present application provides a pharmaceutical composition comprising the mutant and / or immunoconjugate, and optionally a pharmaceutically acceptable carrier or excipient.

[0030] In certain embodiments, the present application provides a pharmaceutical composition comprising the mutant, and optionally a pharmaceutically acceptable carrier or excipient.

[0031] In certain embodiments, the present application provides a pharmaceutical composition comprising the immunoconjugate, and optionally a pharmaceutically acceptable carrier or excipient.

[0032] On the other hand, the present application provides a use of the pharmaceutical composition in preparing a medicament for treating a subject with a solid tumor.

[0033] In another aspect, the present application provides a method for treating a disease in a subject, the method comprising administering to the subject an effective amount of the immunoconjugate described herein and / or the pharmaceutical composition described herein.

[0034] The present application provides interleukin-21 (IL-21) mutants, immunoconjugates of interleukin-21 mutants and anti-PD-1 antibodies, and the use of the interleukin-21 mutants or their immunoconjugates in the preparation of drugs for treating subjects with solid tumors. The affinity of the interleukin-21 mutant for the IL-21 receptor (IL-21R) is significantly reduced compared to the affinity of wild-type IL-21 for the IL-21 receptor (IL-21R). At the same time, the immunoconjugate of the interleukin-21 mutant and the anti-PD-1 antibody increases the expression of the fusion heavy chain, improves stability, and reduces the tendency to aggregate compared to the anti-PD-1-wild-type IL-21 immunoconjugate. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 Schematic diagram of the molecular form of the immunoconjugate.

[0036] Figure 2 Figure 2 is the result of SDS-PAGE electrophoresis of immunoconjugate, where: Figure 2 A and Figure 2B is the SDS-PAGE electrophoresis result of the sample after protein A affinity purification; Figure 2 C and Figure 2 D is the SDS-PAGE electrophoresis result of the sample after ion exchange purification. DETAILED DESCRIPTION

[0037] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0038] Example 1: Design and construction of immunoconjugates of anti-hPD-1 antibodies and IL-21 mutants

[0039] The immunoconjugate molecules of the present invention are in the form of Figure 1 As shown, it includes two parts: a first monomer and a second monomer.

[0040] 1. Anti-hPD-antibody-IL-21 mutant immunoconjugate (N022)

[0041] 1) The first monomer: comprising the light chain and heavy chain of pembrolizumab (prepared by the method described in patent CN104945508B). The CH3 amino acid of the heavy chain of pembrolizumab has been modified as follows: the 366th T (threonine) of the CH3 amino acid sequence of the heavy chain has been mutated to S (serine), the 368th L (leucine) has been mutated to A (alanine), the 407th Y (tyrosine) has been mutated to V (valine), the 349th Y (tyrosine) has been mutated to C (cysteine), and the 447th K (lysine) has been deleted;

[0042] 2) The second monomer: includes the light chain and heavy chain of pembrolizumab (prepared by the method described in patent CN104945508B), a flexible amino acid linker and an IL-21 mutant. Among them, the amino acid sequence of the CH3 of the heavy chain of pembrolizumab is mutated from T (threonine) at position 366 to W (tryptophan), S (serine) at position 354 to C (cysteine), and K (lysine) at position 447 is deleted. The C-terminus of the pembrolizumab is fused to the IL-21 mutant and connected using the flexible amino acid GGGGSGGGGSGGGGS (3x(4GS)). The IL-21 mutant is as follows: the R (arginine) at positions 85 and 86 of the amino acid sequence of the wild-type IL-21 is mutated to G (glycine), the K (lysine) at position 88 is mutated to G (glycine), the R (arginine) at position 90 is mutated to E (glutamic acid), the R (arginine) at position 5 and the P (proline) at position 78 are both mutated to C (cysteine), and a disulfide bond is formed between the two mutated C (cysteines).

[0043] 2. Anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035)

[0044] 1) The first monomer: comprising the light chain and heavy chain of pembrolizumab (prepared by the method described in patent CN104945508B). The CH3 amino acid of the heavy chain of pembrolizumab has been modified as follows: the 366th T (threonine) of the CH3 amino acid sequence of the heavy chain has been mutated to S (serine), the 368th L (leucine) has been mutated to A (alanine), the 407th Y (tyrosine) has been mutated to V (valine), the 349th Y (tyrosine) has been mutated to C (cysteine), and the 447th K (lysine) has been deleted;

[0045] 2) The second monomer: includes the light chain and heavy chain of pembrolizumab (prepared by the method described in patent CN104945508B), a flexible amino acid linker and an IL-21 mutant. Among them, the amino acid sequence of the CH3 of the heavy chain of pembrolizumab is mutated from T (threonine) at position 366 to W (tryptophan), S (serine) at position 354 to C (cysteine), and K (lysine) at position 447 is deleted. The C-terminus of the pembrolizumab is fused to the wild-type IL-21 and connected using the flexible amino acid GGGGSGGGGSGGGGS (3x(4GS)).

[0046] The amino acid sequence information of the immunoconjugates of anti-hPD-1 antibody-IL-21 mutant and anti-hPD-1 antibody-wild-type IL-21 used in the examples is shown in Table 1 below.

[0047] Table 1: Amino acid sequence information of immunoconjugates

[0048]

[0049] Example 2: Preparation and purity detection of anti-hPD-1 antibody-IL-21 mutant immunoconjugate

[0050] The amino acid sequences of N022 and N035 molecules were codon optimized and synthesized, and the target genes were amplified by polymerase chain reaction (PCR). After 1% agarose gel electrophoresis and gel recovery, the heavy chain and light chain genes were constructed into pcDNA3.4 vectors respectively.

[0051] The above plasmids were co-transfected into Expi-CHO cells using the PEI transfection method, and the plasmid transfection ratio was 1:1:1. After transfection, the cells were placed at 37 °C, 8% CO2, and 120 rpm for shaking culture for 16-20 hours. After adding 7.5% (v / v) OPM-CHOProFeed (P81279, Aopuma), the shake flask was placed at 32 °C, 120 rpm, and 8% CO2 for shaking culture. On the third and fifth days after transfection, 7.5% (v / v) feed was added, and the sugar content was kept above 4 g / L. When the cell viability was less than 60%, the cell supernatant was harvested, and after centrifugation and filtration, the cell supernatant was harvested, and the supernatant molecular expression titer was determined by a biochemical analyzer (Credex Bio, Roche).

[0052] Protein A affinity purification (Mab SelectSuRe, Cytiva): Add the harvested cell supernatant to a chromatography column treated with an equilibrium solution (20 mM PBS pH=7.4), and wash the column with the equilibrium solution to remove nonspecific binding proteins. Then rinse the column with 3 column volumes of elution buffer (0.1 M Glycine-Hcl pH=3.0), collect the eluate, add a neutralizing solution (1 M Tris-Hcl pH=7.4), and use an ultrafiltration concentration tube to exchange it into PBS buffer, and calculate the yield. The purity of the immunoconjugate was determined using SDS-PAGE (ExpressPlus™ PAGE Gel, GenScript) and a capillary electrophoresis instrument (PA800 Plus, SCIEX), respectively. The results are shown in Tables 2, 3, and Figure 2 shown.

[0053] Ion exchange purification (Capto S, Cytiva): Cation exchange chromatography was used to further separate the heterodimer molecules and remove homodimer impurities. The eluate was also exchanged into PBS buffer using an ultrafiltration tube, and the concentration (A280) was determined. The purity of the immunoconjugate was determined using the same method as above. The results are shown in Table 2 and Figure 2 shown.

[0054] Table 2. Immunoconjugate yields and concentrations

[0055]

[0056] From Table 2 and Figure 2A and 2B show that the yield and concentration of the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035) were high after one-step affinity purification, but the heavy chain band of the second monomer was shallow after SDS-PAGE (reducing) electrophoresis; while the yield of the anti-hPD-1 antibody-IL-21 mutant immunoconjugate (N022) could reach 106.1 mg / L and the concentration was 1.18 mg / mL, and the proportion of the second monomer heavy chain was significantly higher. Combined with non-reducing SDS-PAGE electrophoresis, it is suggested that N035 has fewer correctly paired heterodimer molecules, while N022 has more correctly paired heterodimer molecules.

[0057] Depend on Figure 2 As can be seen from C and 2D, after ion exchange purification, the proportion of the second monomer heavy chain in the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035) increased, and the proportion of heterodimer molecules increased; the second monomer homodimer and small molecular weight impurities in the anti-hPD-1 antibody-IL-21 mutant immunoconjugate (N022) were removed.

[0058] Table 3 Purity of immunoconjugates purified by protein A affinity (CE-SDS, reduced)

[0059]

[0060] As can be seen from Table 3, compared with the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035), the second monomer heavy chain ratio of the anti-hPD-1 antibody-IL-21 mutant immunoconjugate (N022) was increased by 25.36%.

[0061] Example 3: Binding of immunoconjugates to IL-21R

[0062] Elisa was used to detect the binding of the immunoconjugate of anti-hPD-1 antibody-IL-21 mutant to IL-21R. IL-21R-his (2 ug / mL) was coated and blocked with 2% BSA. The immunoconjugate was diluted to 100 nM, then diluted 3 times and added to the ELISA plate, 100 uL per well. A positive control (wild-type IL-21 fusion Fc protein (i.e., IL-21-Fc) is a fusion of wild-type IL-21 with the N-terminus of human IgG1 Fc) and a negative control (pembrolizumab) were set up, incubated at 37 °C for 1 h and then washed. Subsequently, the plate was diluted at a ratio of 1:5000, HRP-goat anti-human IgG secondary antibody was added, and the plate was incubated at 37 °C for 1 h and then washed. TMB colorimetric solution was added for 3-5 min, and the color development was stopped by adding the stop solution. OD450 was detected by an ELISA reader (Infinite F50, Tecan). The results are shown in Table 4.

[0063] Table 4 Antibody binding activity detection

[0064]

[0065] From the above results, we can see that the EC of N022 50 The EC of IL-21-Fc was 12.98. 50 It can be seen that the activity of N022 in binding to IL-21R is significantly reduced compared with IL-21-Fc. 50 The EC of N022 is 5.33. 50 It is 2.4 times that of N035. This indicates that the binding activity of the anti-hPD-1 antibody-IL-21 mutant immunoconjugate (N022) of the present application to IL-21R is significantly lower than that of the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035).

[0066] Example 4: Stability test of hPD-1 antibody-IL-21 mutant immunoconjugate

[0067] The thermal stability and aggregation tendency of the immunoconjugate were tested using a multifunctional protein stability analyzer (Uncle, UNCHAINED LABS). After centrifugation, the sample was diluted to 1 mg / mL with PBS (20 mM, pH=7.4) and centrifuged again at room temperature at 12000rpm for 2 min. 10 µL of each diluted sample was added to the Uni tube in duplicate, sealed, and the Tm and Tagg values ​​were tested on the machine. The results are shown in Table 5.

[0068] Table 5 Stability results of immunoconjugates

[0069]

[0070] As can be seen from Table 5, the Tm (melting temperature) and Tagg (aggregation temperature) values ​​of the hPD-1 antibody-IL-21 mutant immunoconjugate (N022) are close to those of the monoclonal antibody. The Tm1 (melting temperature 1) of the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035) is similar to that of the monoclonal antibody, but Tm2 (melting temperature 2) is not measured. Tagg266 (aggregation temperature at a wavelength of 266nm for static light scattering) and Tagg473 (aggregation temperature at a wavelength of 473nm for static light scattering) are 4-6 °C lower than those of the monoclonal antibody. This indicates that compared with the anti-hPD-1 antibody-wild-type IL-21 immunoconjugate (N035), the hPD-1 antibody-IL-21 mutant immunoconjugate (N022) has better thermal stability and is not prone to aggregation.

[0071] The present invention has been illustrated by various specific embodiments. However, it will be understood by those skilled in the art that the present invention is not limited to the specific embodiments, and that those skilled in the art can make various changes or modifications within the scope of the present invention, and that the various technical features mentioned in various places in this specification can be combined with each other without departing from the spirit and scope of the present invention. Such changes and modifications are all within the scope of the present invention.

Claims

1. An interleukin-21 (IL-21) mutant, characterized in that Compared with wild-type IL-21, the mutant is: the R at positions 85 and 86 of the amino acid sequence of wild-type IL-21 is mutated to G, the K at position 88 is mutated to G, the R at position 90 is mutated to E, the R at position 5 and the P at position 78 are both mutated to C, and a disulfide bond is formed between the two mutated Cs. The amino acid sequence of the wild-type IL-21 is shown in SEQ ID NO.6, and the amino acid sequence of the mutant is shown in SEQ ID NO:

4.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the interleukin-21 (IL-21) mutant according to claim 1.

3. An immunoconjugate, characterized in that The immunoconjugate is a fusion protein of the interleukin-21 mutant and anti-PD-1 antibody according to claim 1, wherein The interleukin-21 mutant is attached to the Fc of the anti-PD-1 antibody via a GGGGS linker; The anti-PD-1 antibody is pembrolizumab; The fusion protein is: two light chains, each of which has an amino acid sequence as shown in SEQ ID NO:3; a heavy chain, the amino acid sequence of the heavy chain is shown in SEQ ID NO:1; and a heavy chain fused with an interleukin-21 mutant, the amino acid sequence of the fused heavy chain is shown in SEQ ID NO:

5. 4 . A kit comprising the mutant according to claim 1 or the immunoconjugate according to claim 3 .

5. A pharmaceutical composition comprising the immunoconjugate according to claim 3, and optionally a pharmaceutically acceptable carrier or excipient.

6. A pharmaceutical composition comprising the mutant according to claim 1, and optionally a pharmaceutically acceptable carrier or excipient.

7. Use of the pharmaceutical composition of claim 5 in the preparation of a medicament for treating a subject with a solid tumor.